SKYE BIOSCIENCE DL -,001 Aktie

Skye Bioscience received a notice from Nasdaq that it does not meet listing rule 5550(b)(1) because shareholders’ equity as of June 30, 2026 was −$497,307, below the required minimum of $2.5 million. The stock remains tradable on the Nasdaq Capital Market for now; the company has until October 2, 2026 to submit a plan to regain compliance, and if accepted Nasdaq can extend the deadline to February 14, 2027. According to the notice, Skye Bioscience is evaluating various measures to restore compliance and demonstrate the required minimum equity. » More on de.investing.com

The board of directors of Skye Bioscience approved resetting the exercise price for all employee options issued before December 31, 2025 to $0.6150 per share; the change affects options on 2,420,978 common shares. Beneficiaries include CEO Punit Dhillon (1,103,959 options) and COO Tuan Diep (396,295 options); all other terms remain unchanged. In addition, John P. Sharp was appointed chief financial officer effective March 31, 2026; his CFO services will be paid under a Master Services Agreement with a monthly flat fee of $25,600 for up to 64 working hours, and there are no reportable transactions or familial relationships. » More on de.investing.com

Skye Bioscience treated the first patient in part C of an expansion study of Nimacimab and is testing intravenous weekly doses of 400 mg and 600 mg over 15 weeks, followed by a 12-week follow-up. Each cohort includes eight participants, randomized 3:1 versus placebo, with enrollment in the 600 mg group contingent on a positive safety review after the 400 mg period. The goal is to collect preliminary safety and pharmacokinetic data to inform a dosing decision for possible combination therapies with incretins; topline results are expected in Q4 2026. The company emphasizes that the IV doses are intended to achieve higher peripheral tissue exposure; the stock is trading closer to its 52-week low, while the balance sheet shows more cash than short-term liabilities according to the data. » More on de.investing.com